Literature DB >> 1379189

Restricted alpha/beta receptor gene usage of idiotype-specific major histocompatibility complex-restricted T cells: selection for CDR3-related sequences.

H R Snodgrass1, A M Fisher, E Bruyns, B Bogen.   

Abstract

We have sequenced the T cell receptor (TcR) V alpha and V beta genes of seven independent BALB/c CD4+ T cell clones specific for the immunoglobulin lambda 2 light chain produced by the MOPC 315 myeloma (lambda 2(315)). All the clones recognize a peptide of residues 91-101 of lambda 2(315) and are restricted by the major histocompatibility complex (MHC) molecule I-E(d). The results indicate that in BALB/c mice, this anti-idiotypic response uses a very limited number of TcR. The four clones which cross-react between Phe94 and Tyr94 peptide analogues use very similar receptors (V alpha 3, J alpha 1, V beta 6, J beta 1.1). The V alpha 3 gene used by all of these clones is identical and has not been previously described. Although the four clones differ in nucleotide sequence in the V/J borders, two had identical receptors at the amino acid level. One of the cross-reactive clones exhibits a heteroclitic response to the Tyr94 peptide variant resulting from a single amino acid exchange in the V/J junction of the alpha chain. The three remaining clones which recognize only the Phe94 and not the Tyr94 peptide have somewhat more diverse TcR, however, two of these three clones use V beta 6. One of these non-crossreacting clones is alloreactive, the specificity of which can be attributed to differences in the N-D-J sequences. Taken together these data indicate that this T cell response to an immunoglobulin idiotope is very restricted in terms of the TcR used. These data in conjunction with recently published results indicate that, although there can be strong preference for individual V alpha or V beta gene segments, certain V alpha/V beta combinations are preferentially selected for interacting with a given peptide/MHC combination, and that the CDR3-related regions are crucial for antigen fine specificity and alloreactivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379189     DOI: 10.1002/eji.1830220832

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA.

Authors:  Kristin S Gunnarsen; Elin Lunde; Per E Kristiansen; Bjarne Bogen; Inger Sandlie; Geir Å Løset
Journal:  BMC Biotechnol       Date:  2010-02-03       Impact factor: 2.563

2.  Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins.

Authors:  Elin Lunde; Geir Åge Løset; Bjarne Bogen; Inger Sandlie
Journal:  BMC Biotechnol       Date:  2010-08-24       Impact factor: 2.563

3.  A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza.

Authors:  Ranveig Braathen; Heidi Cecilie Larsen Spång; Daniëla Maria Hinke; Jana Blazevski; Sonja Bobic; Even Fossum; Bjarne Bogen
Journal:  Mol Ther Methods Clin Dev       Date:  2020-01-25       Impact factor: 6.698

4.  Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display.

Authors:  Kristin S Gunnarsen; Solveig G Kristinsson; Sune Justesen; Terje Frigstad; Søren Buus; Bjarne Bogen; Inger Sandlie; Geir Åge Løset
Journal:  Sci Rep       Date:  2013-01-29       Impact factor: 4.379

5.  Lymphomas can develop from B cells chronically helped by idiotype-specific T cells.

Authors:  Michael M Zangani; Marianne Frøyland; Gao Yue Qiu; Leonardo A Meza-Zepeda; Jeffery L Kutok; Keith M Thompson; Ludvig A Munthe; Bjarne Bogen
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

6.  Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.

Authors:  S A Kalams; R P Johnson; A K Trocha; M J Dynan; H S Ngo; R T D'Aquila; J T Kurnick; B D Walker
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.